Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
ARGEN-X 2018 nieuws THE BIG SURPRISER FOR NEXT YEARS 2018 nieuws
Volgen
Dag Ooievaar, niet meteen een reden, denk ik. Eerder een combinatie van factoren als het afgelopen mindere sentiment + de zomerperiode + weinig nieuws te verwachten voorlopig... Maar het najaar komt er met stille schreden aan :) Cf ook het Beursig forum en check de post van Lama Dalai om 7u45
daar gaan we : argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115, an antibody targeting the novel immuno-oncology target glycoprotein A repetitions predominant (GARP). "We are very excited by AbbVie's decision to exercise its option to license and develop ARGX-115, given its compelling track record in oncology. We are proud of the work that this milestone represents for argenx - both in efficiently advancing a premier Innovative Access Program candidate to clinical development and in facilitating wider recognition of the important research out of the de Duve Institute / Université Catholique de Louvain around this first-in-class target," said Tim Van Hauwermeiren, Chief Executive Officer of argenx. "Our Innovative Access Program remains a strategic priority for us, capitalizing on the combined strengths of the argenx antibody platform and the deep disease biology expertise at research institutions. We continue to seek out cutting-edge research and targets while advancing our current collaborations, all with the potential to broaden our pipeline and demonstrate our discipline as a strategic partner." "Immuno-oncology is one of AbbVie's key focus areas in our mission to discover and develop medicines that drive transformational improvements in cancer treatment," said Tom Hudson, M.D., Vice President, Oncology Early Discovery and Development, AbbVie. "Our collaboration with argenx over the past two years has been productive, and we look forward to continue working together to fuel scientific progress for patients." argenx and AbbVie entered into an option and license agreement for ARGX-115 in April 2016. With the option exercise announced today, AbbVie obtains a worldwide, exclusive license to develop and commercialize ARGX-115-based products. argenx is now eligible to potentially receive development, regulatory and commercial milestone payments of up to $625 million, as well as tiered royalties on ARGX-115-based product sales, if approved. argenx also has the right to co-promote ARGX-115-based products in the EU and Swiss Economic Area. About ARGX-115 ARGX-115 employs argenx's SIMPLE Antibody(TM) technology and binds specifically to the protein glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active transforming growth factor beta (TGF-beta). ARGX-115 is believed to selectively limit the immunosuppressive activity of activated regulatory T-cells (Tregs), thereby stimulating the immune system to attack cancer cells. While the normal function of Tregs is to suppress certain compartments of the immune system to prevent self-directed immune responses through the release of active TGF-beta, Tregs can also prevent the immune system from recognizing and suppressing pathogenic cells including cancer cells. argenx believes the selective inhibition of TGF-beta release by Tregs is potentially superior to systemic inhibition of TGF-beta activity or depletion of Tregs and may give rise to therapeutic products with an improved safety profile. ARGX-115 was discovered under argenx's Innovative Access Program with the de Duve Institute / Université Catholique de Louvain / WELBIO and exclusively licensed under a research and option agreement in 2013. About the Innovative Access Program (IAP) Through the IAP, argenx collaborates closely with academic centers of excellence and emerging biotechnology companies, bringing cutting-edge antibody discovery technologies to the heart of novel target research. The extraordinary diversity of the immune repertoires comprising its SIMPLE Antibody(TM) Platform streamlines target validation, transforming novel protein discoveries into next generation therapeutic antibody programs. About argenx argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx's ability to execute on this focus is enabled by its suite of differentiated antibody technologies. The SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates.
Dat is goed nieuws. (Maar het is wel Abbvie;)
Waar stond dit nieuws te lezen zo vroeg.. Op welke site... Tx
22 augustus 2018 Breda, Nederland / Gent, België - argenx (Euronext & Nasdaq: ARGX), een biotechnologiebedrijf in de klinische fase dat een diepgaande pijplijn van gedifferentieerde op antilichamen gebaseerde therapieën voor de behandeling van ernstige auto-immuunziekten en kanker ontwikkelt, heeft vandaag de oefening van AbbVie aangekondigd van zijn exclusieve licentie-optie voor de ontwikkeling en commercialisering van ARGX-115, een antilichaam gericht tegen de nieuwe immuno-oncologie doel glycoproteïne A herhalingen overheersend (GARP). "We zijn zeer verheugd over de beslissing van AbbVie om gebruik te maken van de optie om ARGX-115 te licentiëren en ontwikkelen, vanwege zijn indrukwekkende staat van dienst in de oncologie." We zijn trots op het werk dat deze mijlpaal vertegenwoordigt voor argenx, zowel bij het efficiënt bevorderen van een vooraanstaand Innovatief Toegangsprogramma. Kandidaat tot klinische ontwikkeling en in het faciliteren van bredere erkenning van het belangrijke onderzoek van het de Duve Instituut / Université Catholique de Louvain rond dit first-in-class doel, "zei Tim Van Hauwermeiren, CEO van argenx. "Ons Innovative Access-programma blijft een strategische prioriteit voor ons, waarbij we profiteren van de gecombineerde krachten van het argenx-antilichaamplatform en de diepgaande biologie-expertise van onderzoeksinstellingen." We blijven zoeken naar baanbrekend onderzoek en doelen terwijl we onze huidige samenwerkingen bevorderen, allemaal met de potentie om onze pijplijn te verbreden en onze discipline als strategische partner te demonstreren. " "Immuno-oncologie is een van AbbVie's belangrijkste aandachtsgebieden in onze missie om geneesmiddelen te ontdekken en te ontwikkelen die transformerende verbeteringen in de behandeling van kanker stimuleren", aldus Tom Hudson, MD, Vice President, Oncology Early Discovery and Development, AbbVie. "Onze samenwerking met argenx in de afgelopen twee jaar is productief en we kijken ernaar uit om samen verder te werken aan het bevorderen van de wetenschappelijke vooruitgang voor patiënten." argenx en AbbVie sloten in april 2016 een optie- en licentieovereenkomst voor ARGX-115 af. Met de vandaag aangekondigde optie-oefening verkrijgt AbbVie een wereldwijde, exclusieve licentie voor de ontwikkeling en commercialisering van op ARGX-115 gebaseerde producten. argenx komt nu in aanmerking voor het ontvangen van ontwikkelings-, regelgevende en commerciële mijlpaalbetalingen van maximaal $ 625 miljoen, evenals gelimiteerde royalty's op ARGX-115-gebaseerde productverkoop, indien goedgekeurd. argenx heeft ook het recht om op ARGX-115 gebaseerde producten mede te promoten in de EU en de Zwitserse Economische Ruimte.
Thx Jodu voor dit bericht
Blij dat ik afgelopen weken niets verkocht heb. Denk dat de Nasdaq (die gisteravond al vooruitliep op het nieuws) de actie van Abbvie ook wel weet te waarderen. Hierbij vergeleken is Galapagos maar een kneus. Hoeveel incasseert Argenx eigenlijk upfront?
Met optie-oefening bedoelt men zeker optie-uitoefening (exercise)! Zie origineel press-release op de Argen-X site:www.argenx.com/en-GB/news-internal/ar...
Toch jammer dat er niks bekend wordt gemaakt van een e.v.t. upfront bij uitoefenen licentie. Mag hopen dat daar ook nog enkele miljoenen aan verbonden in. Destijds 40 milj bij opstellen contract..
In de VS stijgt het aandeel een "magere" 4% (voorbeurs):seekingalpha.com/news/3384779-argenx-...
Tom3 schreef op 22 augustus 2018 11:22 :
... Hoeveel incasseert Argenx eigenlijk upfront?
Ik denk niks, anders had dat wel in het PB gestaan.
Toch niet echt super onthaald op nasdaq. Terug naar 77,7
www.fiercebiotech.com/biotech/abbvie-... AbbVie licenses GARP checkpoint inhibitor from Argenx
corporate presentation augustus 2018 www.argenx.com/handlers/downloa ... t-2018.pdf Nog te verwachten nieuws met grote impact op de koers ! 3de kwartaal ( zitten we in ) Immune Thrombocytopenia 3Q18: Phase 2 topline resultsT-Cell Lymphoma ASH18: Phase 2 topline results CTCLAcute Myeloid Leukemia ASH18: Phase 1 full data in AML/MDS Myasthenia Gravis 2H18: Start Phase 3 Lees meer op: beursig.com/forum/viewtopic.php?f=4&a... Tx Bioscience
vanuit de nieuwskamer van Bolero: BRIEF-Argenx Receives Feedback From Japan's PMDA On Phase 3 Clinical Trial 07:06 (29/08) - Bron: Reuters Aug 29 (Reuters) - ARGENX SE ARGX.BR : * REG-ARGENX RECEIVES FEEDBACK FROM JAPAN'S PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY PATHWAY FOR EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS * DATA FROM PLANNED GLOBAL PHASE 3 REGISTRATION TRIAL, IF POSITIVE, TO SERVE AS BASIS TO SUBMIT FOR MARKETING AUTHORIZATION IN JAPAN * PLANS TO INITIATE GLOBAL PHASE 3 REGISTRATION TRIAL OF EFGARTIGIMOD IN GMG BEFORE END OF 2018 * EXPECTS DATA FROM PLANNED GLOBAL PHASE 3 REGISTRATION TRIAL, IF POSITIVE, WILL SERVE AS BASIS TO SUBMIT FOR MARKETING AUTHORIZATION IN JAPAN. * GLOBAL PHASE 3 TRIAL EXPECTS TO ENROLL APPROXIMATELY 150 PATIENTS WITH GMG, INCLUDING PATIENTS FROM JAPAN AS WELL AS NORTH AMERICA AND EUROPE * DATA, IF POSITIVE, MAY SERVE AS BASIS FOR BIOLOGICS LICENSE APPLICATION IN U.S. BASED ON FEEDBACK FROM FDA * PATIENTS CAN ROLL OVER INTO AN OPEN-LABEL EXTENSION STUDY FOR A PERIOD OF ONE YEAR Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
83... Groot nieuws op komst? Partner
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis September 6, 2018Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a global Phase 3 registration trial of efgartigimod (ARGX-113) in patients with generalized myasthenia gravis (gMG)."The dosing of the first patient represents an important milestone in advancing efgartigimod towards registration with the hopes of providing more therapeutic options for gMG patients globally. With planned enrollment of 150 patients, this will be the broadest trial of its kind in gMG, and the first to address both acetylcholine receptor (AChR) autoantibody positive as well as AChR autoantibody negative patients like those with MuSK MG," commented Nicolas Leupin, CMO of argenx. "Our Phase 2 results in gMG demonstrated rapid and sustained benefits in disease scores, correlating with a fast and deep reduction of auto-antibodies and a favorable tolerability profile, which we will continue to study in the Phase 3 trial."The randomized, double-blind, placebo-controlled, multicenter trial will enroll approximately 150 patients with gMG in North America, Europe and Japan. The global Phase 3 trial will evaluate the efficacy of a 10 mg/kg intravenous (IV) dose of efgartigimod over a 26-week period. The company expects to enroll AChR autoantibody positive patients and also AChR autoantibody negative patients whose disease is driven primarily by MuSK and LRP4 autoantibodies. The decision to include both patient subgroups results from the significant IgG reductions seen across all four IgG isotypes in the Phase 2 MG trial and the Phase 1 healthy volunteer trial. Patients in the Phase 3 clinical trial will be able to roll over into an open-label extension trial for a period of one year. The primary endpoint of the trial is efficacy as assessed by the Myasthenia Gravis Activities of Daily Living (MG-ADL) score and secondary and other endpoints include additional efficacy, safety, tolerability, quality of life and impact on normal daily activities measures.In the Phase 2 clinical trial of efgartigimod in gMG, data showed clinical improvement of efgartigimod over placebo results through the entire 11-week duration of the trial. Efgartigimod was well-tolerated in all patients, with most adverse events (AEs) characterized as mild and deemed unrelated to the study drug. No serious or severe AEs were reported.
Argenx (advies KBC Securities: "Opbouwen" - koersdoel 87 euro) Argenx laat weten dat de eerste patiënt gedoseerd is in de Efgartigomod fase III-studie bij diagnose Myasthenia Gravis, die naar verwachting vóór eind 2018 zou starten. In totaal zullen 150 patiënten intraveneus worden behandeld met Efgartigimod gedurende een periode van 26 weken. De mening van KBC Securities: Analiste Sandra Cauwenberghs stelt vast dat Argenx zijn leidende positie in het domein behoudt. De fase III-studie verloopt volgens aanvankelijk gecommuniceerde tijdlijnen en zit dus goed op schema. De tweede helft van 2018 wordt voor Argenx belangrijk wat betreft publicatie van resultaten voor verschillende studies.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee